NCT06304545View on ClinicalTrials.gov

Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 15, 2024

Primary Completion Date

August 16, 2026

Study Completion Date

March 15, 2027

Conditions
Rectal Cancer
Interventions
DRUG

Camrelizumab

Camrelizumab IV 200mg

DRUG

Chemotherapy

Capecitabine PO oxaliplatin IV

RADIATION

Radiotherapy

Radiotherapy 50Gy /45Gy /25 fractions

All Listed Sponsors
lead

Harbin Medical University

OTHER

NCT06304545 - Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab | Biotech Hunter | Biotech Hunter